DNMT1 and posterior cortical atrophy: As sarcosine can trigger the development of chemoresistance to various anticancer agents (Merlos Rodrigo et al., 2017), it can be expected that a combination therapy utilizing Dnmt inhibitors and cytostatic drugs could be beneficial for treatment of aggressive PCa.